Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anti-infective Therapy"
DOI: 10.1080/14787210.2022.2128766
Abstract: ABSTRACT Background Long-term outcome data from real-world studies on the implementation of a two-drug dolutegravir plus lamivudine (DTG+3TC) regimen for the treatment of human immunodeficiency virus (HIV) infection remain limited. This study evaluated the real-world… read more here.
Keywords: dtg 3tc; world; dolutegravir plus; art ... See more keywords
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)–infected Participants With HIV-1 RNA
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1083
Abstract: Background Limited data exist on initial human immunodeficiency virus type 1 (HIV-1) treatment with dolutegravir plus lamivudine. Methods A5353 is a phase 2, single-arm, pilot study of once-daily dolutegravir (50 mg) plus lamivudine (300 mg)… read more here.
Keywords: 500000 copies; treatment; plus lamivudine; hiv rna ... See more keywords
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial
Sign Up to like & getrecommendations! Published in 2018 at "Clinical Infectious Diseases"
DOI: 10.1093/cid/cix1131
Abstract: Clinical Trials Registration NCT02263326. read more here.
Keywords: human immunodeficiency; maintains human; plus lamivudine; immunodeficiency virus ... See more keywords
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults
Sign Up to like & getrecommendations! Published in 2022 at "Medicine"
DOI: 10.1097/md.0000000000031100
Abstract: Limited real-world data on dolutegravir (DTG) plus lamivudine (3TC) for HIV-1-infected individuals have been reported. This study aimed to evaluated the real-world efficacy and safety of DTG + 3TC in ART-naïve HIV-1-infected adults in China.… read more here.
Keywords: infected adults; hiv; hiv infected; plus lamivudine ... See more keywords
Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of acquired immune deficiency syndromes"
DOI: 10.1097/qai.0000000000002787
Abstract: BACKGROUND Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine could be an effective and well-tolerated option for simplification in HIV-1 positive patients. We aimed to assess long-time efficacy and safety in… read more here.
Keywords: years dolutegravir; plus lamivudine; hiv; five years ... See more keywords
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients
Sign Up to like & getrecommendations! Published in 2018 at "PLoS ONE"
DOI: 10.1371/journal.pone.0203452
Abstract: Background Simplification strategies of antiretroviral treatment represent effective tools for the reduction of drug-induced toxicity, resistance mutations in case of virological failure and costs. Objectives To assess the effectiveness of simplification to atazanavir/ritonavir (ATVrtv) or… read more here.
Keywords: treatment; plus lamivudine; hiv; unboosted atazanavir ... See more keywords
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks)
Sign Up to like & getrecommendations! Published in 2022 at "Viruses"
DOI: 10.3390/v14030524
Abstract: Brief: Real-world data in naïve HIV-1 patients demonstrate that dolutegravir plus lamivudine in a multiple tablet regimen is effective, safe, and satisfactory; it causes moderately increasing weight and abdominal circumference and is administrable on a… read more here.
Keywords: real life; dolutegravir plus; week; plus lamivudine ... See more keywords